▶ 전체 게시글 텍스트
I started looking at this after the Novo suit dropped and kept pulling threads. Figured I’d post the risk map because the bull and bear takes I keep seeing here miss the same thing. People argue HIMS like it’s one company. It’s two.
Business A is the cash pay subscription platform: hair, ED, derm, mental health. Recurring revenue, no insurance friction. That engine is real and I’m not here to dunk on it.
Business B was the GLP1 compounding era. A national funnel built around a regulatory perimeter that was never meant for mass market distribution. That perimeter tightened, the stock got repriced, and now the whole debate is whether they can unwind that exposure without snapping the core.
Before governance, before narrative, the thing that matters is unit economics.
Subscriber growth isn’t the flex people think it is if the economics under each subscriber drift the wrong way. You don’t need subs to collapse to get a nasty rerate. You just need the platform to get more expensive to grow.
From what’s been publicly reported: non GLP ARPU went from roughly $60 to $55 in a single quarter, Q2 2025. Blended ARPU fell from roughly $84 to $74 over the same window. Marketing was about $218M in Q2 2025 against roughly 73,000 net new subs, which is about $3,000 per marginal add. Gross margin went from roughly 82% in FY2023 to roughly 74% by Q3 2025. Mix and fulfillment complexity doing what they always do to high margin platform narratives.
None of that means the company’s dead. It just means the bull case has to be tighter than they have 2.5M subscribers. The real argument is: they can still acquire and retain profitably in a post headline world. If you can’t make that case, everything else is vibes.
Now, the 88% lockout.
HIMS is effectively controlled by the CEO through a dual class structure. Class A gets one vote. Class V gets 175 votes. Roughly 88% of total voting power sits with the CEO group. He also holds Chairman and committee seats, which narrows internal friction exactly when friction is supposed to protect you as a shareholder.
This doesn’t make him evil. It just means outcomes get more binary. When it works, it’s fast. When it doesn’t, there’s no one to pull the brake. You’re underwriting one person’s judgment whether you want to or not.
Regulatory and legal. This is where comment sections go stupid, so I’ll keep it tight.
This isn’t compounding is illegal now. Patient specific compounding in narrow lawful use cases is a completely different universe from a nationwide, ad driven, subscription checkout GLP1 funnel. The risk sits in the gap between compounding as a clinical exception and compounding as a scaled consumer product.
Once enforcement shifts toward copycat framing, the business model gets targeted, not just the drug category. Even if you think they keep some version of weight loss revenue, the question is whether they keep the scaled version that actually moved the needle.
And litigation doesn’t need a court loss to hurt you. The process is a tax: fees, distraction, settlement leverage that never fully goes away. Translation: they may keep offering weight loss solutions. The risky part is the national funnel built on a regulatory edge.
Okay. The math people keep dodging: the 2030 converts.
About $1B in zero coupon convertible notes due May 2030. Conversion price $70.67. Stock’s around $16. Those notes behave like cash debt, not equity dilution.
Base case: they’ve reported about $1.1B cash and roughly $300M a year free cash flow. Four years of that is about $1.2B. Add the cash and you’re around $2.3B of firepower against $1B due. That can work.
Downside case, the one that actually matters: if GLP1 unwinds fast and free cash flow drops to $100M to $150M a year, four years gives you $400M to $600M. Starting cash $1.1B plus that generation equals $1.5B to $1.7B. Pay the notes and you’re left with $0.5B to $0.7B for everything. Ops, marketing, legal drain. Not bankruptcy. But it turns into a refinancing and capital allocation story that gets louder every quarter the GLP1 line deteriorates. The notes don’t care what you call the pivot. They care whether the cash shows up.
Where I land: neutral.
HIMS can survive if the GLP1 transition happens in an orderly way and subscriber economics stabilize. If revenue drops faster than management can replace it while legal pressure escalates, this flips from a growth story to a balance sheet story before 2030.
What would change my mind: GLP1 exposure declining without a cliff, non GLP unit economics stabilizing, and legal and regulatory outcomes staying bounded.
If you want my quick framing: best case, the GLP1 line shrinks gracefully or transitions to compliant alternatives and the core keeps printing. Middle case, the core lives but growth slows and it trades like a prove it story. Worst case, you get an abrupt operational hit, CAC rises, margins compress, and the 2030 notes become the overhang everyone pretends not to see.
Next things I’m watching are guidance on earnings, any legal or regulatory move that forces immediate operational changes, and unit economics trend ex GLP.
One question for bulls: if you strip out GLP1 entirely, what’s your steady state CAC for the core platform after a year of negative headlines? Because that number decides whether the core is durable or just big.
Disclosure: no position. Public info only. Not investment advice.
Edit: cleaned up some formatting, added the Q2 ARPU numbers I’d left out of the first draft.